Biologics  ||| S:0 E:10 ||| NNP
in  ||| S:10 E:13 ||| IN
the  ||| S:13 E:17 ||| DT
treatment  ||| S:17 E:27 ||| NN
of  ||| S:27 E:30 ||| IN
rheumatoid  ||| S:30 E:41 ||| JJ
arthritis  ||| S:41 E:51 ||| NN
and  ||| S:51 E:55 ||| CC
ankylosing  ||| S:55 E:66 ||| NNS
spondylitis  ||| S:66 E:78 ||| VBP
There  ||| S:78 E:84 ||| EX
are  ||| S:84 E:88 ||| VBP
clear  ||| S:88 E:94 ||| JJ
differences  ||| S:94 E:106 ||| NNS
in  ||| S:106 E:109 ||| IN
the  ||| S:109 E:113 ||| DT
clinical  ||| S:113 E:122 ||| JJ
picture  ||| S:122 E:130 ||| NN
and  ||| S:130 E:134 ||| CC
in  ||| S:134 E:137 ||| IN
the  ||| S:137 E:141 ||| DT
pathogenesis  ||| S:141 E:154 ||| NN
between  ||| S:154 E:162 ||| IN
rheumatoid  ||| S:162 E:173 ||| JJ
arthritis  ||| S:173 E:183 ||| NN
( ||| S:183 E:184 ||| -LRB-
RA ||| S:184 E:186 ||| NNP
)  ||| S:186 E:188 ||| -RRB-
and  ||| S:188 E:192 ||| CC
ankylosing  ||| S:192 E:203 ||| JJ
spondylitis  ||| S:203 E:215 ||| NNS
( ||| S:215 E:216 ||| -LRB-
AS ||| S:216 E:218 ||| NNP
) ||| S:218 E:219 ||| -RRB-
.  ||| S:219 E:221 ||| .
Biologic  ||| S:221 E:230 ||| JJ
agents  ||| S:230 E:237 ||| NNS
targeting  ||| S:237 E:247 ||| VBG
TNF-alpha  ||| S:247 E:257 ||| NNS
are  ||| S:257 E:261 ||| VBP
efficacious  ||| S:261 E:273 ||| VBN
in  ||| S:273 E:276 ||| IN
both  ||| S:276 E:281 ||| DT
diseases ||| S:281 E:289 ||| NNS
,  ||| S:289 E:291 ||| ,
with  ||| S:291 E:296 ||| IN
some  ||| S:296 E:301 ||| DT
tendency  ||| S:301 E:310 ||| NN
to  ||| S:310 E:313 ||| TO
work  ||| S:313 E:318 ||| VB
even  ||| S:318 E:323 ||| RB
better  ||| S:323 E:330 ||| JJR
in  ||| S:330 E:333 ||| IN
spondyloarthritides  ||| S:333 E:353 ||| NNS
( ||| S:353 E:354 ||| -LRB-
SpA ||| S:354 E:357 ||| NNP
)  ||| S:357 E:359 ||| -RRB-
on  ||| S:359 E:362 ||| IN
a  ||| S:362 E:364 ||| DT
clinical  ||| S:364 E:373 ||| JJ
basis ||| S:373 E:378 ||| NN
.  ||| S:378 E:380 ||| .
However ||| S:380 E:387 ||| RB
,  ||| S:387 E:389 ||| ,
anti-TNF  ||| S:389 E:398 ||| JJ
therapy  ||| S:398 E:406 ||| NN
was  ||| S:406 E:410 ||| VBD
shown  ||| S:410 E:416 ||| VBN
to  ||| S:416 E:419 ||| TO
inhibit  ||| S:419 E:427 ||| VB
radiographic  ||| S:427 E:440 ||| JJ
progression  ||| S:440 E:452 ||| NN
in  ||| S:452 E:455 ||| IN
RA  ||| S:455 E:458 ||| NNP
but  ||| S:458 E:462 ||| CC
not  ||| S:462 E:466 ||| RB
in  ||| S:466 E:469 ||| IN
AS ||| S:469 E:471 ||| NNP
.  ||| S:471 E:473 ||| .
This  ||| S:473 E:478 ||| DT
is  ||| S:478 E:481 ||| VBZ
probably  ||| S:481 E:490 ||| RB
due  ||| S:490 E:494 ||| JJ
to  ||| S:494 E:497 ||| TO
the  ||| S:497 E:501 ||| DT
outstanding  ||| S:501 E:513 ||| JJ
difference  ||| S:513 E:524 ||| NN
in  ||| S:524 E:527 ||| IN
pathogenesis ||| S:527 E:539 ||| NNS
:  ||| S:539 E:541 ||| :
while  ||| S:541 E:547 ||| IN
in  ||| S:547 E:550 ||| IN
RA  ||| S:550 E:553 ||| NNP
osteodestructive  ||| S:553 E:570 ||| VBD
lesions  ||| S:570 E:578 ||| JJ
such  ||| S:578 E:583 ||| JJ
as  ||| S:583 E:586 ||| IN
erosions  ||| S:586 E:595 ||| JJ
predominate ||| S:595 E:606 ||| NN
,  ||| S:606 E:608 ||| ,
AS  ||| S:608 E:611 ||| NNP
patients  ||| S:611 E:620 ||| NNS
will  ||| S:620 E:625 ||| MD
rather  ||| S:625 E:632 ||| RB
develop  ||| S:632 E:640 ||| VB
osteoproliferative  ||| S:640 E:659 ||| JJ
changes  ||| S:659 E:667 ||| NNS
such  ||| S:667 E:672 ||| JJ
as  ||| S:672 E:675 ||| IN
syndesmophytes ||| S:675 E:689 ||| NN
.  ||| S:689 E:691 ||| .
There  ||| S:691 E:697 ||| EX
is  ||| S:697 E:700 ||| VBZ
some  ||| S:700 E:705 ||| DT
evidence  ||| S:705 E:714 ||| NN
that  ||| S:714 E:719 ||| IN
anti-TNF  ||| S:719 E:728 ||| JJ
agents  ||| S:728 E:735 ||| NNS
may  ||| S:735 E:739 ||| MD
show  ||| S:739 E:744 ||| VB
longterm  ||| S:744 E:753 ||| JJ
efficacy  ||| S:753 E:762 ||| NN
and  ||| S:762 E:766 ||| CC
acceptable  ||| S:766 E:777 ||| JJ
safety  ||| S:777 E:784 ||| NN
profiles  ||| S:784 E:793 ||| NNS
over  ||| S:793 E:798 ||| IN
5-10  ||| S:798 E:803 ||| JJ
years ||| S:803 E:808 ||| NNS
.  ||| S:808 E:810 ||| .
There  ||| S:810 E:816 ||| EX
are  ||| S:816 E:820 ||| VBP
some  ||| S:820 E:825 ||| DT
differences  ||| S:825 E:837 ||| NNS
between  ||| S:837 E:845 ||| IN
the  ||| S:845 E:849 ||| DT
agents.Whether  ||| S:849 E:864 ||| CD
the  ||| S:864 E:868 ||| DT
recent  ||| S:868 E:875 ||| JJ
developments  ||| S:875 E:888 ||| NNS
of  ||| S:888 E:891 ||| IN
targeted  ||| S:891 E:900 ||| JJ
therapies  ||| S:900 E:910 ||| NNS
in  ||| S:910 E:913 ||| IN
RA  ||| S:913 E:916 ||| NNP
with  ||| S:916 E:921 ||| IN
agents  ||| S:921 E:928 ||| NNS
such  ||| S:928 E:933 ||| JJ
as  ||| S:933 E:936 ||| IN
rituximab ||| S:936 E:945 ||| NN
,  ||| S:945 E:947 ||| ,
abatacept  ||| S:947 E:957 ||| NN
and  ||| S:957 E:961 ||| CC
tocilizumab  ||| S:961 E:973 ||| NNS
will  ||| S:973 E:978 ||| MD
also  ||| S:978 E:983 ||| RB
work  ||| S:983 E:988 ||| VB
for  ||| S:988 E:992 ||| IN
AS  ||| S:992 E:995 ||| NNP
is  ||| S:995 E:998 ||| VBZ
unknown  ||| S:998 E:1006 ||| VBN
at  ||| S:1006 E:1009 ||| IN
present ||| S:1009 E:1016 ||| JJ
.  ||| S:1016 E:1018 ||| .
